MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bcr-2025-264962

Медицинская библиотека · BMJ case reports · 2025

Clinical insights: atezolizumab-induced myositis mimicking hepatic injury.

Agarwal Bhumi, Sharma Mansi, Batra Ullas, Choudhury Ritwika, Sharma Meha

СтатьяКлинический случайПеревод в очереди

Аннотация

Atezolizumab is an immune checkpoint inhibitor that targets PDL-1 (programmed death ligand-1) on the tumour cells and inactivates it. The addition of this drug to chemotherapy has led to survival benefits in the treatment of small cell lung cancer-extensive stage (SCLC-ES). However, these excellent outcomes may be marred by the development of immune-mediated adverse events (irAEs). The pathophysiology of these irAEs is not well defined, and as a result, they are less understood as an entity. In addition to this, the highly non-specific presentation and unawareness among treating physicians may lead to delays in diagnosis and subsequently affect patient outcomes. Immunotherapy-induced myositis is one such rare irAE.Herein, we present a case of a male in his early 70 s undergoing treatment for SCLC-ES, who initially presented with non-specific symptoms and grade four transaminitis and was subsequently diagnosed with atezolizumab-related myositis after comprehensive evaluation. The patient was managed successfully and has an ongoing response more than 6 months after stopping immunotherapy and 18 months since initial diagnosis. This case report aims to address the knowledge gap regarding this irAE with insights on diagnosis and management.

Для цитирования: Agarwal Bhumi, Sharma Mansi, Batra Ullas, Choudhury Ritwika, Sharma Meha. Clinical insights: atezolizumab-induced myositis mimicking hepatic injury.. BMJ case reports. 2025. DOI: 10.1136/bcr-2025-264962.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.